Northern Trust
REVB icon

Northern Trust’s Revelation Biosciences REVB Stock Holding History

Northern Trust’s Portfolio REVB Stock Details REVB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-5,477
Closed -$17.5K – 4510
2025
Q4 		$17.5K Buy
+5,477
New +$24K ﹤0.01% 4403

Other funds holding REVB

AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
SM
Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM
XT
XTX Topco George Town, Cayman Islands $5.75B AUM 30.56% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return
SS
SBI Securities Tokyo, Japan $4.4B AUM 74.25% 1-Year Est. Return
HI
Harbour Investments Madison, Wisconsin $6.48B AUM 18.23% 1-Year Est. Return

Northern Trust's REVB Position: Q1 2026 in Review

Northern Trust sold out of Revelation Biosciences (REVB) in Q1 2026, closing a stake of 5,477 shares — an estimated $17.5K sold.

Northern Trust first reported a position in REVB in Q4 2025 and held it in 1 quarter. The position peaked at $17.5K in Q4 2025. 12 funds tracked by Wall St. Rank hold REVB as of Q1 2026.

  • Northern Trust reported no remaining Revelation Biosciences position as of Q1 2026 after selling out during the quarter.
  • Northern Trust sold 5,477 Revelation Biosciences shares in Q1 2026, an estimated $17.5K.
  • Northern Trust first reported a position in Revelation Biosciences in Q4 2025 and held it in 1 quarter.
  • Northern Trust's Revelation Biosciences position peaked at $17.5K in Q4 2025.
  • 12 funds tracked by Wall St. Rank held Revelation Biosciences as of Q1 2026.

Based on Northern Trust's 13F filing for Q1 2026, filed 14 May 2026.